A Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PRA023 in Subjects with Systemic Sclerosis Associated with Interstitial Lung Disease (SSc-ILD) PR200-104
09/20/2022 - 09/20/2025 (Subcontract PI)PPD Development LLC Prometheus Bio, Inc
A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients with Diffuse Cutaneous
11/12/2021 - 11/11/2024 (PI)Horizon Therapeutics
IgPro10_2001 A Randomized, Multicenter, double blind, placebo controlled, Phase 2 study to evaluate the efficacy and safety of IgPro10 (Intravenous Immunoglobulin, Privige) For the treatment of Adult
08/27/2020 - 08/27/2023 (PI)CSL Behring LLC
A PHASE 2 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF IFETROBAN IN PATIENTS WITH DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS
03/15/2019 - 03/14/2023 (PI)Kadmon Corporation, LLC
Protocol # ML30172 - Scleroderma Lung Study III: Combining of anti-fibrotic effects of Pirfenidone with Mycophenolate to treat scleroderma-related interstitial lung disease
06/29/2018 - 02/28/2023 (PI)University of California, Los Angeles
Protocol # 1199.225, An open-label extension trial to assess the long term safety of nintedanib in patients with‘Systemic Sclerosis associated Interstitial Lung Disease’ (SSc-ILD)
02/08/2018 - 02/07/2023 (PI)Boehringer Ingelheim Pharmaceuticals, Inc.
Genome Research in African American Sclerodema Patients (GRASP)
04/05/2017 - 04/04/2022 (Subcontract PI)Johns Hopkins University Scleroderma Res Fdn
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
10/18/2017 - 02/28/2022 (PI)Corbus Pharmaceuticals Holdings, Inc.
Protocol # ITN075AI, (BRAVOS) - Evaluation of Brentuximab Vedotin in Diffuse Cutaneous Systemic Sclerosis
02/01/2017 - 01/31/2022 (Subcontract PI)Benaroya Research Institute at Virginia Mason NIH NIAID2UM1AI109565-08
Protocol #CPI-IFE-004 "A Phase 2 Randomized, Double-blind, Placebo-Controlled Study to Assess the safety and efficacy of Ifetroban in Patients with Diffuse Cutaneous Systemic Sclerosis or Systemic-Scl
01/03/2019 - 01/03/2021 (PI)Cumberland Pharmaceuticals Inc.
Showing 10 of 11 results.
Show All Results
Abatacept (CTLA4_Ig) For the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyaugiitis (Wegener's) (ABROGATE)
03/10/2015 - 03/09/2020 (Subcontract PI)Cleveland Clinic Foundation Bristol-Myers Squibb